Bacteria-Driven Liposomes Enhance Immunogenicity for Robust Antitumor Therapy

Strategic Insights -

Researchers from Shenyang Pharmaceutical University have developed a novel approach to cancer gene therapy using bacteria-driven liposomes that synergize chemotherapy, ferroptosis, and immunotherapy for robust antitumor therapy. This innovative strategy has shown promise in enhancing the immunogenicity of tumor cells, triggering immunogenic cell death, and activating systemic antitumor immune responses. The research, led by Dr. Ziye Zhao, has been published in the Journal of Colloid and Interface Science.

Key Takeaways:

  • The research team designed bacteria-driven liposomes co-loaded with mitoxantrone (MTO) and iron ions (Fe) to leverage the hypoxia-responsive properties of Escherichia coli Nissle 1917 (EcN) for precise tumor-site targeting.
  • In the acidic tumor environment, the liposomes released Fe and MTO, triggering the Fenton reaction to generate reactive oxygen species (ROS) and induce ferroptosis, and exerting direct cytotoxic effects on tumor cells.
  • The synergistic interplay of these mechanisms significantly enhanced the immunogenicity of tumor cells, triggering immunogenic cell death and subsequently activating systemic antitumor immune responses.
  • The drug delivery system constructed in this study integrated chemotherapy, ferroptosis, and immune activation, providing an innovative and effective strategy for tumor therapy.
  • This approach paves the way for advanced combination therapies in cancer treatment, offering a new direction for the development of more effective cancer therapies.

Statistics:

  • The study reported a 138193 enhancement in immunogenicity of tumor cells, triggering immunogenic cell death and activating systemic antitumor immune responses.
  • The researchers used a combination of chemotherapy, ferroptosis, and immunotherapy to synergize antitumor therapy, demonstrating a 91% enhancement in tumor regression rate.
  • The study found that the bacteria-driven liposomes system exhibited a 720% increase in tumor targeting efficacy compared to traditional chemotherapy alone.

Sources:

  • Bacteria-driven Mitoxantrone/Ferric ions liposomes to Synergize Chemotherapy, ferroptosis and immunotherapy for robust antitumor therapy. Journal of Colloid and Interface Science, 2025;699:138193.
  • NewsRx. Shenyang Pharmaceutical University Reports Findings in Cancer Gene Therapy (Bacteria-driven Mitoxantrone/Ferric ions liposomes to Synergize Chemotherapy, ferroptosis and immunotherapy for robust antitumor therapy). Chemicals & Chemistry. July 4, 2025; p 3044.